A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Protein responsible for ‘bad’ blood vessel growth discovered
26 July 2013
The discovery of a protein that encourages blood vessel growth, and especially ‘bad’ blood vessels – the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis – has been reported in the journal Nature.
The team at the UCL Institute of Ophthalmology discovered the new protein, called LRG1, by screening for mouse genes that are over-expressed in abnormal retinal blood vessels in diseased eyes.
In these diseased retinas the LRG1 protein is expressed by blood vessel endothelial cells, which line blood vessel walls. LRG1 is also present in the eyes of patients with proliferative diabetic retinopathy – a vascular complication of diabetes that can lead to blindness.
The study shows that, in mouse models, LRG1 promotes the growth of blood vessels in a process known as ‘angiogenesis’. Conversely, inhibition of LRG1 in mouse models reduces the harmful blood vessel growth associated with retinal disease.
The authors of the study suggest that blocking LRG1’s activity is a promising target for future therapy.
UCL Business (UCLB) has invested Proof of Concept funding into the development of an antibody therapy against Lrg1. Following this investment the Medical Research Council invested £750k to develop a humanised antibody. UCLB has filed two patent families covering this technology. Angiogenesis is an essential biological process that is required for development, reproduction and the repair of damaged tissues. However angiogenesis also plays a major role in many diseases such as age related macular degeneration (AMD), diabetic retinopathy and cancer where new vessel growth can be harmful.
Vascular endothelial growth factor (VEGF) is a regulator of angiogenesis and the anti-VEGF therapeutics, Lucentis and Eylea, are two of the few blockbuster drugs of recent times with annual sales of $1bn and $800m respectively.
While the anti-VEGF therapies block all angiogenesis Lrg1 is selective for pathogenic angiogenesis. Professor John Greenwood, senior author of the research from the UCL Institute of Ophthalmology said: “We have discovered that a secreted protein, LRG1, promotes new blood vessel growth and its inhibition prevents pathological blood vessel growth in ocular disease.
“Our findings suggest that LRG1 has less of a role in normal blood vessel growth and so may be particularly applicable to ‘bad’ blood vessel growth. This makes LRG1 an especially attractive target for therapeutic intervention in conditions where vessel growth contributes to disease.”
The mechanism through which LRG1 promotes angiogenesis is by modifying the signalling of a multifunctional secreted growth factor called transforming growth factor beta (TGF-beta). TGF-beta regulates both the maintenance of normal healthy blood vessels, and the unwanted growth of harmful blood vessels, but precisely how it promotes two opposing outcomes is a biological paradox.
This study indicates that in the retinal diseases investigated LRG1 production is ‘turned on’ in blood vessels. This causes a switch in TGF-beta signalling away from a normal vessel maintenance pathway towards a pathway that promotes the growth of new harmful blood vessels.
Professor Stephen Moss, senior author from the UCL Institute of Ophthalmology said: “Genetic studies have revealed that the gene that codes for LRG1 is conserved in vertebrates, and this study confirms that mouse and human blood vessels express LRG1.
“We predict, therefore, that abnormal blood vessel growth is also a conserved process and that the role of LRG1 is equally applicable to human pathological angiogenesis.”
UCLB is currently in discussions with potential licensees with regards to the therapeutic being developed.
The research was funded by the Medical Research Council, the Lowy Medical Research Foundation, UCL Business, the Rosetrees Trust, the National Institute for Health Research (NIHR) Biomedical Research Centre at MoorfieldsEyeHospital and UCL Institute of Ophthalmology (who are advising on the translational pathway) and the British Heart Foundation.
For further information about this technology, contact Dr Rachel, Senior Business Manager at UCLB. Email: firstname.lastname@example.org Tel: +44 (0)20 7679 9000